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S U M M A R Y
Objective: Evidence available to date indicates that dengue viruses 1, 2, and 3 could be among the causes
of acute fever in eastern Africa. Recently, four reports on dengue infection in travelers and residents have
raised concerns over the occurrence of dengue fever in mainland Tanzania and in Zanzibar. The objective
of this study was to provide seroprevalence data on dengue infection in Tanzania.
Methods: This study was conducted in 2007 at two peripheral hospitals, one on Pemba Island, Zanzibar
and one in Tosamaganga, Iringa Region, mainland Tanzania. Two hundred and two consecutive febrile
outpatients were studied for antibodies and viral RNA to assess the circulation of dengue virus in
Tanzania.
Results: A seroprevalence of 7.7% was found on Pemba Island and of 1.8% was found in Tosamaganga. No
acute cases and no previous infections among patients under 11 years of age were detected.
Conclusion: These ﬁndings provide the ﬁrst baseline data on dengue seroprevalence in the country. No
recent dengue virus circulation in Tanzania and in the Zanzibar archipelago up until the early 1990s is
reported.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Dengue virus (DENV) infection is the most rapidly spreading
mosquito-borne tropical disease in the world, with a 30-fold
increase in incidence in the last 50 years.1 Between 50 and 100
million dengue infections occur annually worldwide, accounting
for 20 000–70 000 deaths per year.1 Children under 5 years of age
are particularly affected, with a case fatality ratio between 0.5%
and 3.5% in Asian countries.1 Since dengue infection is not ofﬁcially
notiﬁed by most African countries, little is known about the
epidemiology of the illness on this continent. Despite the co-
circulation of all four dengue serotypes, no severe disease
epidemics have occurred in Africa.
Although surveillance data are poor, some information
provided by imported cases of dengue infection shows that§ Data from this study were reported in the form of an oral presentation at the 9th
Societa` Italiana di Malattie Infettive e Tropicali (SIMIT) Conference, Rome, Italy,
November 24–27, 2010.
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evidence indicates that DENV-1, DENV–2, and DENV–3 could be
among the causes of acute fever in eastern Africa. Examples of this
are outbreaks in the Comoros in various years (1948, 1984, and
1993; DENV-1 and DENV-2) and in Pemba, Mozambique (1984–
1985; DENV-3).3,4 Another outbreak of dengue caused by DENV-2
was reported in the city of Djibouti in 1991–1992.5 A recent cross-
sectional survey in healthy subjects conducted in Kenya reported a
seroprevalence of 1.1% and a yearly incidence of 8.5/1000 persons.6
Co-circulation of different dengue virus serotypes was also
reported among troops from the USA engaged in the Operation
Restore Hope mission in Somalia (1992–1993). The authors
reported 2% of dengue cases caused by DENV-3 and 41% by
DENV-2.7 Interestingly, no cases of severe dengue were reported.
Recently, four reports of DENV infection in travelers and
residents have raised concerns over the occurrence of dengue fever
in Tanzania and Zanzibar.8–11 There has been great concern for the
likely occurrence of a DENV-3 outbreak in the United Republic of
Tanzania. Moi et al. reported two cases of imported DENV-3
infection in Japanese travelers returning from Tanzania,8 and that
same year, a case was reported in a European traveler returningses. Published by Elsevier Ltd. All rights reserved.
Table 1
Dengue seroprevalence in different age groups: percentage and number of positive
samples over total tested samples.
Age 1–14 years Age 15 years All patients
Area
Tosamaganga 0 (0/51) 3.3 (2/60) 1.8 (2/111)
Pemba 1.9 (1/52) 15.4 (6/39) 7.7 (7/91)
All patients 1.0 (1/103) 8.1 (8/99) 4.5 (9/202)
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case at the National Institute for Infectious Diseases (Istituto
Nazionale per le Malattie Infettive; INMI) ‘‘L. Spallanzani’’ in Rome
in a febrile adult patient returning from Zanzibar.10 A dispatch on
May 17, 2010 reported the occurrence of 17 suspected dengue
fever cases since April 2010 at a private clinic in Dar es Salaam,
mostly among resident expatriates who had traveled to Zanzibar.11
Finally, on July 27, 2010, the Tanzanian Daily News (a local
newspaper) reported the occurrence of 100 acute cases of dengue
fever in Dar es Salaam and Zanzibar. No baseline data from this
geographical area are available in the literature on dengue
seroprevalence in the general population or on dengue incidence
in febrile patients.
2. Methods
This study involved banked serum from febrile patients
enrolled in a cross-sectional survey conducted in the outpatient
departments of two peripheral hospitals in Tanzania in February
and March 2007: the Chake Chake Hospital on Pemba Island,
Zanzibar and the Tosamaganga Missionary Hospital in Iringa
Region, as already published.12 Ethical approval for the study was
obtained from the ethics committee of the National Institute for
Medical Research, Dar es Salaam, Tanzania, the ethics committee of
the Ministry of Health and Social Welfare of Zanzibar, and the
ethics committee of INMI. Written informed consent was obtained.
A questionnaire in Kiswahili (national language of Tanzania) was
provided for the collection of epidemiological and clinical data.
Inclusion and exclusion criteria were the same as those of the
above-mentioned approved study protocol. In detail, inclusion
criteria were age 1 year and a temperature of 38 8C for <10
days; exclusion criteria were the presence of signs of any severe
disease, including complicated falciparum malaria, according to
the World Health Organization (WHO) deﬁnition given in 2001.13
Patients affected by mental illness, or with a clinical picture clearly
referring to other diseases (such as measles, chickenpox, otitis,
infected wounds, or chest X-ray documented pneumonia), or with
previous anti-malarial treatment, were also excluded.
Two specimens of venous blood (5 ml into a serum separator
tube, 5 ml into a vial containing ethylenediaminetetraacetic acid
(EDTA)) were collected from each enrolled patient. For cases from
whom it was not feasible to collect 10 ml (youngest ages)
peripheral blood was collected on dried paper. All blood samples
were dispatched to the INMI Spallanzani in Rome, Italy. The
samples were stored at 80 8C in the biorepository facility of the
institute.
Anti-DENV IgG and IgM antibodies in serum samples were
determined by indirect immunoﬂuorescence assay (IFA) using
home-made slides, carried out with a mix of uninfected and DENV-
2 (New Guinea C strain) infected Vero E6 cells. We assessed the
diagnostic accuracy of the assay by testing well-characterized
human sera in parallel on the home-made slides and on
commercial slides (EUROIMMUN Medizinische Labordiagnostika
AG, Lu¨beck, Germany): no differences between the two methods
were observed.
Anti-chikungunya virus (CHIKV) IgG and IgM antibodies were
determined by IFA using home-made slides, carried out with a mix
of uninfected and CHIKV (LR2006 OPY-1 strain; kindly supplied by
R.N. Charrel of Poˆle Maladies Infectieuses et Microbiologie, AP-HM
Timone, Marseille, France) infected Vero E6 cells. To assess the
diagnostic accuracy of the assay, our laboratory participated with
successful proﬁciency in an external quality assurance (EQA)
exercise run by the European Network for Diagnostics of
‘‘Imported’’ Viral Diseases (ENIVD).14
For the detection of ﬂaviviruses and chikungunya virus, total
RNA was extracted from serum specimens using the BioRobot MDxand QIAamp Virus BioRobot MDx Kit (Qiagen, Hilden, Germany).
The RNA was then screened for the presence of DENV RNA using a
pan-ﬂavivirus hemi-nested reverse transcription (RT)-PCR that
ampliﬁes a 250-bp portion of the NS5 gene of human pathogenic
ﬂavivirus.15 To detect chikungunya virus, an RT-PCR that ampliﬁes
a 354-bp portion of the nsP1 gene was used.16
Data were logged, processed, and analyzed using SPSS v.15.0 for
Windows software package (SPSS Inc., Chicago, IL, USA). Frequen-
cies were compared using the Chi-square test (or Fisher’s exact test
when applicable).
3. Results
A total of 202 febrile patients were studied to detect anti-
dengue IgG and IgM antibodies in serum samples from Tosama-
ganga (111, 55.0%) and Pemba (91, 45.0%). Of the total 202 patients,
99 (49.0%) were adults, mainly from Tosamaganga (60, 60.6%); 103
patients (51.0%) were children under 15 years of age, equally
represented at both sites. Data on sex were not available for one
anti-DENV IgG negative patient. Among the remaining 201 tested
patients, there were slightly more females (n = 112) than males
(n = 89). The most frequently reported symptoms (other than
fever) were headache (46%), cough (40.6%), joint pain (34.2%), and
vomiting (22.8%). No patients had a skin rash.
Anti-DENV IgG antibodies were found in nine out of 202
patients (4.5%), with no difference between men and women (5/89,
5.6% vs. 4/112, 3.6%, respectively). The IgG prevalence was
signiﬁcantly higher on Pemba than in Tosamaganga (7.7% vs.
1.8%, respectively; p = 0.046), and in adults than in patients under
15 (8.1% vs. 1.0%, respectively; p = 0.03), particularly in Pemba
(15.4% in adults vs. 1.9% in patients under 15; p = 0.046) (Table 1).
In patients aged under 15 years, anti-dengue IgG antibodies were
detected in only one case, an 11-year-old male subject from
Pemba. All but one of the Zanzibar patients with speciﬁc IgG
antibodies were residents in the rural area surrounding the city of
Chake Chake, the main city of Pemba Island. No IgM dengue-
speciﬁc antibodies were found. All 165 patients (81.7%) tested for
DENV RNA resulted negative. No anti-CHIKV antibodies were
detected in the 202 analyzed patients, and all 127 of those (62.9%)
tested for CHIKV RNA resulted negative.
4. Discussion
In this cross-sectional survey of febrile outpatients performed
in 2007, a sporadic transmission of dengue infection with a 4.5%
seroprevalence rate was detected. A signiﬁcantly higher seroprev-
alence was reported among adult patients from Pemba Island,
reaching a rate of 15.4%. No acute cases and no previous infections
among patients younger than 11 years of age were detected. Since
CHIKV and DENV infections have a common route of transmission
through the same vectors, Aedes aegypti and Aedes albopictus, and
since many patients in the present study suffered from joint pain,
the presence of CHIKV was also investigated in serum samples. No
patient had antibodies speciﬁc for CHIKV and none of those tested
had an acute infection.
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immunoﬂuorescence assay for the detection of anti-DENV anti-
bodies, a cross-reactivity with antibodies speciﬁc for other
ﬂaviviruses was not excluded, especially in the absence of IgM
antibodies, virus isolation, or PCR-positive results. Moreover, the
absence of IgM could be explained by considering that most of the
tested patients had had fever for fewer than 5 days (3.4 days on
average) and it is well known that dengue patients sampled before
day 5 of illness may have negative IgM determinations. Neverthe-
less, the absence of DENV RNA by PCR suggests the absence of
acute dengue infection. A comparison of the acute serum with the
convalescent serum from the same patients would have been
useful, but this study was designed as a cross-sectional trial and a
longitudinal follow-up was not included in the protocol. We are
now planning to perform this in the same areas. Second, the
sample size was small and the population studied may not be
representative of the different socio-demographic characteristics
and geographical distribution of the total population.
These ﬁndings provide the ﬁrst baseline data on dengue
seroprevalence in the country. No recent dengue virus circulation
in Tanzania and in the Zanzibar archipelago up until the early
1990s is reported. These results are consistent with the last
ProMED-mail reports that showed an epidemiologic link between
the dengue cases and previous travel in Zanzibar. New studies are
needed to assess the circulation of dengue virus in the coastal areas
of Tanzania, as well as the need for a preparedness plan in the case
of a new outbreak in the next at-risk period.
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